Related Experiment Videos
Summary
Growth hormone therapy for short stature in children is expensive, costing millions annually. This raises ethical questions about the balance between medical capabilities and responsible application of new technologies.
Area of Science:
- Biotechnology
- Pediatric Endocrinology
- Medical Ethics
Background:
- Bioengineered therapies, such as growth hormone (GH) treatment, present significant financial burdens.
- The use of GH for short stature in children highlights the high costs associated with advanced medical interventions.
Purpose of the Study:
- To examine the economic implications and ethical considerations of growth hormone therapy in pediatric short stature.
- To illustrate the common dilemma between the technical feasibility and ethical justification of new medical technologies.
Main Methods:
- Case study analysis of growth hormone therapy.
- Economic expenditure estimation for GH treatment in the U.S.
- Ethical analysis of medical technology adoption.
Main Results:
- Annual U.S. expenditure for growth hormone therapy exceeds $375 million.
- The cost of GH treatment is approximately $20,000 per year for a 30 kg child.
- Significant ethical concerns accompany the high cost and uncertain efficacy of GH therapy.
Conclusions:
- The application of growth hormone therapy exemplifies the gap between medical capability and ethical consideration.
- The rapid advancement of medical technology often outpaces the understanding of its appropriate use and societal impact.